Browsing Tag
Goldman Sachs
168 posts
Goldman Sachs strikes $2.25bn deal for options ETF specialist NEOS
Goldman Sachs will pay up to $2.25 billion for NEOS as active ETF flows heat up, but the price sets a high bar for what the deal delivers by 2027.
Dream Finders to acquire Beazer Homes, creating sixth-largest US homebuilder
Dream Finders raised its bid from $25.75 to $33.50 to secure Beazer at 0.8x book, but Beazer's Q3 loss and DFH's own margin squeeze make execution the test.
Prologis agrees £14.3bn SEGRO takeover in largest 2026 UK REIT deal
Prologis will pay up to £14.3 billion for SEGRO, but H1 2027 closing hinges on shareholder votes, regulatory clearances and a fresh $2.1bn equity raise.
Braveheart Bio IPO targets $1.2bn valuation as HCM drug race heats up
Braveheart Bio is seeking up to $318.8 million in its Nasdaq IPO, but investors must decide whether its cardiac myosin inhibitor can compete in an increasingly crowded hypertrophic cardiomyopathy market.
KKR takes Integer private for $5.7bn as device manufacturing growth slows
KKR’s $5.7 billion Integer deal offers a 52% premium as weaker near-term device sales contrast with durable manufacturing demand.
CBIZ to be taken private by Grant Thornton in largest US accounting M&A in 25+ years
Grant Thornton's $5B cash take-private of CBIZ at 54% premium arrives as Q2 EBITDA fell 14.3%; the only US-listed accounting firm now leaves the NYSE.
Oxylabs bets $3.6bn valuation on agentic AI web data infrastructure thesis
Warburg Pincus injects $130 million into Oxylabs at a $3.6 billion valuation, but can agentic AI data infrastructure defend that private-market benchmark?
Frasers Group (LSE: FRAS) crosses 30% HUGO BOSS threshold as €38 takeover offer enters final week
Frasers Group has moved beyond Germany’s mandatory takeover threshold, but HUGO BOSS shareholder resistance and Frasers’ rising debt leave the final ownership outcome unresolved.
Eli Lilly (NYSE: LLY) to acquire AtaiBeckley in $3.8bn TRD psychedelic deal
Eli Lilly (NYSE: LLY) to acquire AtaiBeckley for $6.75/share cash plus $2.50 CVR, taking the BPL-003 5-MeO-DMT depression asset to Phase 3 read in 2029.
Goldman Sachs stock (NYSE: GS) jumps 7.6% after record quarter: can the gains last?
Goldman Sachs reported record quarterly revenue and EPS as equities trading, underwriting and dealmaking accelerated. With $GS near a 52-week high and valued above three times book value, the next test is whether elevated returns can continue.